2.46
+0.07(+2.93%)
Currency In USD
| Previous Close | 2.39 |
| Open | 2.38 |
| Day High | 2.46 |
| Day Low | 2.35 |
| 52-Week High | 3.22 |
| 52-Week Low | 0.51 |
| Volume | 514,602 |
| Average Volume | 668,140 |
| Market Cap | 138.44M |
| PE | -2.51 |
| EPS | -0.98 |
| Moving Average 50 Days | 2.15 |
| Moving Average 200 Days | 1.66 |
| Change | 0.07 |
If you invested $1000 in Spero Therapeutics, Inc. (SPRO) since IPO date, it would be worth $213.91 as of November 10, 2025 at a share price of $2.46. Whereas If you bought $1000 worth of Spero Therapeutics, Inc. (SPRO) shares 5 years ago, it would be worth $171.07 as of November 10, 2025 at a share price of $2.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
GlobeNewswire Inc.
Nov 04, 2025 9:05 PM GMT
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacteri
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
GlobeNewswire Inc.
Oct 21, 2025 6:00 AM GMT
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with regulatory authorities to support regulatory fili
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
Late breaking session to feature results from the successful PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI)CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a